MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia
Fiche du document
Auteur
Date
12 février 2024
Discipline
Types de document
Périmètre
Identifiant
- doi: 10.58079/vto2
Source
Organisation
Licence
info:eu-repo/semantics/openAccess
Sujets proches
Health care delivery Health services Personal health services Medical services Medical and health care industry Delivery of medical care Health care Healthcare Delivery of health care Products, Manufactured Manufactured goods Products Manufactured products Therapy, Gene illnessCiter ce document
lsgilbert, « MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia », ELSIBI, ID : 10.58079/vto2
Métriques
Partage / Export
Résumé
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020. Read the press release from Medicines and Healthcare products Regulatory Agency published on 16 November 2023.